Voltar
Revisão Revisado por pares
BIBTEX RIS

BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

2007; Massachusetts Medical Society; Volume: 357; Issue: 3 Linguagem: Inglês

10.1056/nejmct071828

ISSN

1533-4406

Autores

Charles A. Schiffer,

Tópico(s)

Chronic Lymphocytic Leukemia Research

Resumo

A 28-year-old woman with recently diagnosed chronic myelogenous leukemia (CML) presents for consideration of appropriate treatment. No siblings are available as candidate donors for stem-cell transplantation. Imatinib, an inhibitor of the BCR-ABL tyrosine kinase present in almost all CML, is recommended. The patient may need to take imatinib indefinitely to maintain suppression of abnormal bone marrow clones.

Referência(s)